Skip to Content

Xatmep FDA Approval History

FDA Approved: Yes (First approved April 25, 2017)
Brand name: Xatmep
Generic name: methotrexate
Dosage form: Oral Solution
Company: Azurity Pharmaceuticals
Treatment for: Acute Lymphoblastic Leukemia, Juvenile Idiopathic Arthritis

Xatmep (methotrexate) is a folate analog metabolic inhibitor in an oral solution formulation indicated for the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and for the management of pediatric patients with active polyarticular juvenile idiopathic arthritis.

Development Timeline for Xatmep

Apr 26, 2017ApprovalFDA Approves Xatmep (methotrexate) Oral Solution

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.